Showing results (21-30 of 82) with videos related to
Sort By:
Pageof 9
Patient Preference and Adherence|April 22, 2025
Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel TherapiesSikander Ailawadhi, Yelak Biru, Solène Clavreul, et al.Frontiers in Medicine|December 11, 2023
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experimentCaitlin Thomas, Sikander Ailawadhi, Rakesh Popat, et al.Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.Ejhaem|October 17, 2024
Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experienceDario Melotti, Samir Asher, Ethan Troy-Barnes, et al.British Journal of Haematology|February 18, 2017
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experienceNicola Maciocia, Andrew Melville, Simon Cheesman, et al.European Radiology|June 29, 2017
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib inductionArash Latifoltojar, Margaret Hall-Craggs, Alan Bainbridge, et al.Journal of the Advanced Practitioner in Oncology|October 9, 2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple MyelomaRakesh Popat, Sagar Lonial, Peter M Voorhees, et al.British Journal of Haematology|May 5, 2022
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosisSriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, et al.Journal of the National Cancer Institute|November 9, 2025
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trialsMaria Mainou, Muatassem Alsadhan, Kalliopi Tsapa, et al.Ejhaem|October 6, 2025
The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre ExperienceDipal Mehta, Maria Gabriel, Nathan Adu-Poku, et al.Pageof 9